S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Forecast, Price & News

$3.73
+0.03 (+0.81%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.67
$3.81
50-Day Range
$2.51
$4.08
52-Week Range
$2.42
$11.50
Volume
25,861 shs
Average Volume
87,956 shs
Market Capitalization
$76.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.75

Syros Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
322.3% Upside
$15.75 Price Target
Short Interest
Healthy
3.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.18) to ($4.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

363rd out of 983 stocks

Pharmaceutical Preparations Industry

172nd out of 486 stocks


SYRS stock logo

About Syros Pharmaceuticals (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Syros Pharmaceuticals (NASDAQ: SYRS)
WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
Q1 2023 Syros Pharmaceuticals Inc Earnings Call
See More Headlines

SYRS Price History

SYRS Company Calendar

Last Earnings
5/10/2023
Today
6/03/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.75
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+322.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-94,650,000.00
Net Margins
-485.12%
Pretax Margin
-754.40%

Debt

Sales & Book Value

Annual Sales
$12.37 million
Book Value
$5.18 per share

Miscellaneous

Free Float
18,444,000
Market Cap
$76.82 million
Optionable
Optionable
Beta
1.67

Key Executives

  • Nancy A. Simonian
    President, Chief Executive Officer & Director
  • Jason Haas
    Chief Financial Officer
  • Eric R. OlsonEric R. Olson
    Chief Scientific Officer
  • David A. Roth
    Chief Medical Officer
  • Conley Chee
    Chief Commercial Officer













SYRS Stock - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 1 year price targets for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.75 in the next twelve months. This suggests a possible upside of 322.3% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 at the beginning of the year. Since then, SYRS stock has increased by 3.9% and is now trading at $3.73.
View the best growth stocks for 2023 here
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.27. The firm earned $2.95 million during the quarter, compared to analysts' expectations of $2.95 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 118.11% and a negative net margin of 485.12%.

When did Syros Pharmaceuticals' stock split?

Shares of Syros Pharmaceuticals reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (3.76%), Ally Bridge Group NY LLC (1.21%), BlackRock Inc. (0.92%), ExodusPoint Capital Management LP (0.60%), Geode Capital Management LLC (0.40%) and Price T Rowe Associates Inc. MD (0.11%). Insiders that own company stock include Eric R Olson, Eric R Olson, Richard A Young, Srinivas Akkaraju and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $3.73.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $76.82 million and generates $12.37 million in revenue each year. The company earns $-94,650,000.00 in net income (profit) each year or ($9.63) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -